» Articles » PMID: 33131456

Universal Access to Essential Medicines As Part of the Right to Health: a Cross-national Comparison of National Laws, Medicines Policies, and Health System Indicators

Overview
Specialty Public Health
Date 2020 Nov 2
PMID 33131456
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Access to essential medicines for the world's poor and vulnerable has made little progress since 2000, except for a few specific medicines such as antiretrovirals for HIV/AIDS. Human rights principles written into national law can create a supportive environment for universal access to medicines; however, systematic research and policy guidance on this topic is lacking.

Objective: To examine how international human rights law and WHO's essential medicines policies are embedded in national law for medicines affordability and financing, and interpreted and implemented in practice to promote universal access to essential medicines.

Methods: This thesis consists of (1) a cross-national content analysis of 192 national constitutions, 71 national medicines policies, and legislation for universal health coverage (UHC) from 16 mostly low- and middle-income countries; (2) a case study of medicines litigation in Uruguay, and (3) a follow-up report of eight right to health indicators for access to medicines from 195 countries.

Results: Some, but not all, of the 12 principles from human rights law and WHO's policy are embedded in national UHC law and medicines policies (part 1). Even the most rights-compliant legislation for access to medicines is subject to the unique and inconsistent interpretation of domestic courts, which may be inconsistent with the right to health in international law (part 2). Many national health systems for which data were available still fail to meet the official targets for eight indicators of access to medicines (part 3).

Conclusions: International human rights law and WHO policy are embedded in national law for essential medicines and practically implemented in national health systems. Law makers can use these findings and the example texts in this thesis as a starting point for writing and monitoring governments' rights-based legal commitments for access to medicines. Future research should study the effect of national law on access to medicines and population health.

Citing Articles

Beyond , Pharmaceutical Molecule Production in Cell-Free Systems and the Use of Noncanonical Amino Acids Therein.

Casteleijn M, Abendroth U, Zemella A, Walter R, Rashmi R, Haag R Chem Rev. 2025; 125(3):1303-1331.

PMID: 39841856 PMC: 11826901. DOI: 10.1021/acs.chemrev.4c00126.


Availability of essential medicines during the COVID-19 pandemic: A qualitative study examining experiences and level of preparedness in Kenya.

Onyango J, Ogira D, Kokwaro G PLOS Glob Public Health. 2024; 4(7):e0002547.

PMID: 39074106 PMC: 11285947. DOI: 10.1371/journal.pgph.0002547.


Availability, pricing, and affordability of essential medicines for pediatric population in Malawi.

Chiumia F, Chithope-Mwale C, Abikoloni F, Matchaya V, Gaviyawo T, Khuluza F Front Pharmacol. 2024; 15:1379250.

PMID: 38666031 PMC: 11043549. DOI: 10.3389/fphar.2024.1379250.


How and why pharmaceutical reforms contribute to universal health coverage through improving equitable access to medicines: a case of Ghana.

Koduah A Front Public Health. 2023; 11:1163342.

PMID: 37483923 PMC: 10360122. DOI: 10.3389/fpubh.2023.1163342.


An Inquiry into State Agreement and Practice on the International Law Status of the Human Right to Medicines.

Forman L, Al-Alami B, Fajber K Health Hum Rights. 2022; 24(2):125-140.

PMID: 36579305 PMC: 9790948.


References
1.
Gotham D, Onarheim K, Barber M . How the MDGs gave up on measuring access to medicines. Lancet Glob Health. 2016; 4(5):e296-7. DOI: 10.1016/S2214-109X(16)00066-8. View

2.
Billington J, Omer S . Use of Fees to Discourage Nonmedical Exemptions to School Immunization Laws in US States. Am J Public Health. 2015; 106(2):269-70. PMC: 4815619. DOI: 10.2105/AJPH.2015.302967. View

3.
Khatib R, Mckee M, Shannon H, Chow C, Rangarajan S, Teo K . Availability and affordability of cardiovascular disease medicines and their effect on use in high-income, middle-income, and low-income countries: an analysis of the PURE study data. Lancet. 2015; 387(10013):61-9. DOI: 10.1016/S0140-6736(15)00469-9. View

4.
Hogerzeil H, Liberman J, Wirtz V, Kishore S, Selvaraj S, Kiddell-Monroe R . Promotion of access to essential medicines for non-communicable diseases: practical implications of the UN political declaration. Lancet. 2013; 381(9867):680-9. DOI: 10.1016/S0140-6736(12)62128-X. View

5.
Bigdeli M, Jacobs B, Tomson G, Laing R, Ghaffar A, Dujardin B . Access to medicines from a health system perspective. Health Policy Plan. 2012; 28(7):692-704. PMC: 3794462. DOI: 10.1093/heapol/czs108. View